# A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation

> **NCT01331993** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers
- Bioequivalence

## Interventions

- **DRUG:** VIMOVO (AstraZeneca)
- **DRUG:** VIMOVO (Patheon)
- **DRUG:** Marketed enteric-coated naproxen formulation

## Key facts

- **NCT ID:** NCT01331993
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2011-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01331993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01331993, "A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01331993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*